Gamco Investors INC. ET AL grew its position in ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 22.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 636,341 shares of the company's stock after purchasing an additional 117,229 shares during the quarter. Gamco Investors INC. ET AL owned approximately 2.29% of ZimVie worth $6,872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of ZIMV. J. Goldman & Co LP boosted its position in shares of ZimVie by 167.5% in the fourth quarter. J. Goldman & Co LP now owns 1,425,810 shares of the company's stock worth $19,890,000 after purchasing an additional 892,785 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of ZimVie by 9.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,244,938 shares of the company's stock worth $17,367,000 after buying an additional 107,461 shares in the last quarter. Ancora Advisors LLC lifted its holdings in shares of ZimVie by 460.8% in the fourth quarter. Ancora Advisors LLC now owns 112,160 shares of the company's stock worth $1,565,000 after buying an additional 92,160 shares in the last quarter. Nuveen LLC purchased a new position in shares of ZimVie in the first quarter worth $901,000. Finally, American Century Companies Inc. lifted its holdings in shares of ZimVie by 10.0% in the first quarter. American Century Companies Inc. now owns 690,675 shares of the company's stock worth $7,459,000 after buying an additional 62,625 shares in the last quarter. 95.63% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on ZIMV shares. Barclays raised shares of ZimVie from an "underweight" rating to an "equal weight" rating and upped their price target for the company from $9.00 to $19.00 in a research note on Tuesday, July 22nd. B. Riley downgraded shares of ZimVie from a "buy" rating to a "neutral" rating and set a $19.00 price target on the stock. in a research note on Thursday, July 31st. Wall Street Zen downgraded shares of ZimVie from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Finally, UBS Group cut their price objective on shares of ZimVie from $16.00 to $10.00 and set a "neutral" rating on the stock in a research report on Thursday, May 15th. Four analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $17.75.
Read Our Latest Stock Analysis on ZIMV
ZimVie Stock Up 0.3%
Shares of ZIMV stock traded up $0.07 during mid-day trading on Tuesday, hitting $18.95. 327,119 shares of the stock traded hands, compared to its average volume of 288,722. The stock has a market cap of $534.25 million, a P/E ratio of -27.06 and a beta of 2.20. The stock's fifty day moving average is $15.21 and its two-hundred day moving average is $11.98. ZimVie Inc. has a 52-week low of $8.15 and a 52-week high of $19.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.37 and a quick ratio of 1.60.
ZimVie (NASDAQ:ZIMV - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.21 by $0.05. The business had revenue of $116.66 million during the quarter, compared to analyst estimates of $112.60 million. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. Equities analysts predict that ZimVie Inc. will post 0.6 EPS for the current year.
About ZimVie
(
Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Read More

Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.